Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2022; 43(04): 349-354
DOI: 10.1055/s-0041-1732859
Original Article

A Retrospective Observational Study of Dicentric (9;12): A Unique, Nonrandom Translocation Defining a Cytogenetic Subgroup with Favorable Outcome in Acute Lymphoblastic Leukemia

S. Shanthala
1   Cytogenetics Unit-Department of Pathology, Kidwai Memorial Institute of Oncology, Bengaluru, Karnataka, India
,
B. L. Kavitha
1   Cytogenetics Unit-Department of Pathology, Kidwai Memorial Institute of Oncology, Bengaluru, Karnataka, India
,
Prasanna Kumari
1   Cytogenetics Unit-Department of Pathology, Kidwai Memorial Institute of Oncology, Bengaluru, Karnataka, India
,
C.R. Vijay
2   Department of Biostatistics, Kidwai Memorial Institute of Oncology, Bengaluru, Karnataka, India
,
D. Lokanatha
3   Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Bengaluru, Karnataka, India
,
L. Appaji
4   Department of Pediatric Oncology, Kidwai Memorial Institute of Oncology, Bengaluru, Karnataka, India
,
Govind Babu
3   Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Bengaluru, Karnataka, India
,
C. S. Premalata
5   Department of Pathology, Kidwai Memorial Institute of Oncology, Bengaluru, Karnataka, India
,
C. Ramachandra
6   Kidwai Memorial Institute of Oncology, Bengaluru, Karnataka, India
› Author Affiliations Funding None.
› Further Information
   Permissions and Reprints

Correction to:

Erratum to: A Retrospective Observational Study of Dicentric (9;12): A Unique, Nonrandom Translocation Defining a Cytogenetic Subgroup with Favorable Outcome in Acute Lymphoblastic LeukemiaIndian J Med Paediatr Oncol eFirst
DOI: 10.1055/s-0042-1743292

Abstract

Introduction Cytogenetic abnormalities are integral to the risk stratification of acute lymphoblastic leukemia (ALL).

Objectives The present study aimed to highlight a rare, yet nonrandom cytogenetic abnormality notably dicentric (9;12), which was observed in ALL patients who presented to our institute. The study analyzed the frequency, clinicohematological features, and treatment response of these patients.

Materials and Methods A single-group observational study was conducted from April 2014 to April 2020. Cytogenetic analysis was done on bone marrow aspirate samples of the patients referred to the cytogenetics laboratory with clinical diagnosis of acute leukemia. Cytogenetic, clinical, and hematological data were collected from respective departmental records, case files, and patients.

Results Dic(9;12) was identified in 1.2% of ALL (19 out of 1,544 patients). They showed striking preponderance in teen and young adult males with characteristic precursor B cell immunophenotype. Majority of these patients displayed favorable risk profiles such as low total count, mild lymphadenopathy and splenomegaly, mild-to-moderate elevation of lactate dehydrogenase, and good response to first induction chemotherapy. Rare coexistence of dic(9;12) with well-established cytogenetic markers such as t(9;22) and t(1;19) was observed.

Conclusion Dic(9;12) is one of the most specific cytogenetic markers of precursor B cell (pre-B) ALL. It defines a subgroup with favorable clinical and biological profile. We suggest inclusion of dic(9;12) in cytogenetic risk stratification of precursor B cell ALL. Long-term follow-up studies are recommended to establish the prognostic significance of this cytogenetic subgroup, which may benefit from less intensive chemotherapy.

Keywords

dicentric (9;12) - precursor B cell acute lymphoblastic leukemia


Publication History

Article published online:
05 October 2021

© 2021. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Borowitz MJ, Chan JK, Downing JR, Le Beau MM, Arber DA. B-lymphoblastic leukaemia/lymphoma with recurrent genetic abnormalities. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H. et al. eds. WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues, Revised. 4th edition.. Lyon: International Agency for Research on Cancer; 2017: 200-209
    Google Scholar
  • 2 Faderl S, Kantarjian HM, Talpaz M, Estrov Z. Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia. Blood 1998; 91 (11) 3995-4019
    CrossrefPubMedGoogle Scholar
  • 3 Carroll AJ, Raimondi SC, Williams DL. et al. tdic(9;12): a nonrandom chromosome abnormality in childhood B-cell precursor acute lymphoblastic leukemia: a Pediatric Oncology Group Study. Blood 1987; 70 (06) 1962-1965
    CrossrefPubMedGoogle Scholar
  • 4 Mackinnon RN, Campbell LJ. The role of dicentric chromosome formation and secondary centromere deletion in the evolution of myeloid malignancy. Genet Res Int 2011; 643628
    PubMedGoogle Scholar
  • 5 An Q, Wright SL, Konn ZJ. et al. Variable breakpoints target PAX5 in patients with dicentric chromosomes: a model for the basis of unbalanced translocations in cancer. Proc Natl Acad Sci U S A 2008; 105 (44) 17050-17054
    CrossrefPubMedGoogle Scholar
  • 6 Smith A, Das P, O'Reilly J, Patsouris C, Campbell LJ. Three adults with acute lymphoblastic leukemia and dic(7;9)(p11.2;p11. Cancer Genet Cytogenet 2006; 166 (01) 86-88
    CrossrefPubMedGoogle Scholar
  • 7 United Kingdom Cancer Cytogenetics Group (UKCCG). Translocations involving 9p and/or 12p in acute lymphoblastic leukemia. Genes Chromosomes Cancer 1992; 5 (03) 255-259
    CrossrefPubMedGoogle Scholar
  • 8 Mahmoud H, Carroll AJ, Behm F. et al. The non-random dic(9;12) translocation in acute lymphoblastic leukemia is associated with B-progenitor phenotype and an excellent prognosis. Leukemia 1992; 6 (07) 703-707
    PubMedGoogle Scholar
  • 9 Behrendt H, Charrin C, Gibbons B. et al. Dicentric (9;12) in acute lymphocytic leukemia and other hematological malignancies: report from a dic(9;12) study group. Leukemia 1995; 9 (01) 102-106
    PubMedGoogle Scholar
  • 10 Md Elbossaty WF. Lactate dehydrogenase (LDH) as prognostic marker in acute leukemia “quantitative method”. J Blood Disord Transfus 2017; 8: 375
    Google Scholar
  • 11 Raimondi SC, Privitera E, Williams DL. et al. New recurring chromosomal translocations in childhood acute lymphoblastic leukemia. Blood 1991; 77 (09) 2016-2022
    CrossrefPubMedGoogle Scholar
  • 12 Huret JL, Heerema NA, Brizard A. et al. Two additional cases of t dic(9:12) in acute lymphocytic leukemia (ALL): prognosis in ALL with dic(9:12. Leukemia 1990; 4 (06) 423-425
    PubMedGoogle Scholar
  • 13 Strehl S, König M, Dworzak MN, Kalwak K, Haas OA. PAX5/ETV6 fusion defines cytogenetic entity dic(9;12)(p13;p13. Leukemia 2003; 17 (06) 1121-1123
    CrossrefPubMedGoogle Scholar
  • 14 Illade L, Fioravantti V, Andion M, Hernandez-Marques C, Madero L, Lassaletta A. Dicentric translocation (9;12) in acute lymphoblastic leukemia: a chromosomal abnormality with an excellent prognosis?. Tumori 2017; 103 (Suppl. 01) e44-e46
    CrossrefPubMedGoogle Scholar
  • 15 Woo JS, Alberti MO, Tirado CA. Childhood B-acute lymphoblastic leukemia: a genetic update. Exp Hematol Oncol 2014; 3: 16
    CrossrefPubMedGoogle Scholar
  • 16 Terwilliger T, Abdul-Hay M. Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer J 2017; 7 (06) e577
    Google Scholar
  • 17 Bargetzi MJ, Mühlematter D, Tichelli A, Jotterand M, Wernli M. Dicentric translocation (9;12) presenting as refractory Philadelphia chromosome-positive acute B-cell lymphoblastic leukemia. Cancer Genet Cytogenet 1999; 113 (01) 90-92
    CrossrefPubMedGoogle Scholar